Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid-β imaging in mouse model of Alzheimer's disease

• DRK092 has higher affinity for fibrillary Aβ and brain uptake than IMPY.
• 125I-DRK092 labeled Aβ deposited in brains of AD patient and mouse in vitro.
• 125I-DRK092 detected Aβ accumulation more sensitively than 125I-IMPY ex vivo.

Non-invasive determination of amyloid-β peptide (Aβ) deposition has important significance for early diagnosis and medical intervention in Alzheimer's disease (AD). In this study, we investigated the availability of a radioiodinated imidazo[1,2-a]pyridine derivative, termed 125I-DRK092, as single photon emission computed tomography (SPECT) ligand for in vivo detection of Aβ deposition. DRK092 showed high binding affinity for either synthetic human Aβ fibrils or brain homogenates from amyloid precursor protein transgenic (Tg) mouse (PS1-ki/JU-Tg2576) and AD patient with a dissociation constant (Kd) of one-digit nM, and excellent brain permeability (peak value of uptake: approximately 0.9% of injection dose/g rat brain). Ex vivo autoradiographic analysis showed that measurement with 125I-DRK092 has higher sensibility for detecting Aβ accumulation than with 125I-IMPY, a well-known amyloid SPECT ligand, in Tg mice. In vitro autoradiography with 125I-DRK092 also confirmed higher accumulation of radioactivity in the cortical area, enriched with Aβ plaques, of Tg mouse and AD patient brains, as compared with the corresponding areas in non-Tg mouse and healthy control brains. All the data presented above lead us to draw the conclusion that radioiodinated DRK092 is a potential SPECT ligand for amyloid imaging in AD.

Figure optionsDownload high-quality image (71 K)Download as PowerPoint slide